Related references
Note: Only part of the references are listed.Kallikrein 6 secreted by oligodendrocytes regulates the progression of experimental autoimmune encephalomyelitis
Yoshio Bando et al.
GLIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Higher levels of kallikrein-8 in female brain may increase the risk for Alzheimer's disease
Kathy Keyvani et al.
BRAIN PATHOLOGY (2018)
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease
Kalicharan Patra et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Neuroinflammation in Neurodegenerative Disorders-a Review
Martin Schain et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
Kallikrein-8 inhibition attenuates Alzheimer's disease pathology in mice
Arne Herring et al.
ALZHEIMERS & DEMENTIA (2016)
Kallikreins - The melting pot of activity and function
Magdalena Kalinska et al.
BIOCHIMIE (2016)
Structural basis for the Zn2+ inhibition of the zymogen-like kallikrein-related peptidase 10
Mekdes Debela et al.
BIOLOGICAL CHEMISTRY (2016)
The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia
Lora Dukic et al.
CLINICAL BIOCHEMISTRY (2016)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack et al.
NEUROLOGY (2016)
Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas
Ilijana Begcevic et al.
CLINICAL PROTEOMICS (2016)
The dynamic blood-brain barrier
James Keaney et al.
FEBS JOURNAL (2015)
Prevalence of Amyloid PET Positivity in Dementia Syndromes A Meta-analysis
Rik Ossenkoppele et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Unleashing the therapeutic potential of human kallikrein-related serine proteases
Ioannis Prassas et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Clearance systems in the brain-implications for Alzheimer disease
Jenna M. Tarasoff-Conway et al.
NATURE REVIEWS NEUROLOGY (2015)
Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β
Jun Jiang et al.
SCIENTIFIC REPORTS (2015)
β-Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau
Amalia Tsolakidou et al.
ALZHEIMERS & DEMENTIA (2013)
Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy
Joshua E. Burda et al.
GLIA (2013)
Reduction and the intracellular translocation of EphB2 in Tg2576 mice and the effects of β-amyloid
M. Qu et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2013)
Kallikrein 6 is a novel molecular trigger of reactive astrogliosis
Isobel A. Scarisbrick et al.
BIOLOGICAL CHEMISTRY (2012)
White matter hyperintensities predict amyloid increase in Alzheimer's disease
Timo Grimmer et al.
NEUROBIOLOGY OF AGING (2012)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Marilyn S. Albert et al.
ALZHEIMERS & DEMENTIA (2011)
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model
Moustapha Cisse et al.
NATURE (2011)
Neuropsin cleaves EphB2 in the amygdala to control anxiety
Benjamin K. Attwood et al.
NATURE (2011)
Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease
Timo Grimmer et al.
BIOLOGICAL PSYCHIATRY (2010)
Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia
Emma L. Ashby et al.
BRAIN RESEARCH (2010)
Incidence of cerebral microbleeds A longitudinal study in a memory clinic population
J. D. C. Goos et al.
NEUROLOGY (2010)
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tero Tapiola et al.
ARCHIVES OF NEUROLOGY (2009)
Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid
Timo Grimmer et al.
BIOLOGICAL PSYCHIATRY (2009)
Early Changes in Hippocampal Eph Receptors Precede the Onset of Memory Decline in Mouse Models of Alzheimer's Disease
Ana Maria Simon et al.
JOURNAL OF ALZHEIMERS DISEASE (2009)
Functional Roles of Human Kallikrein-related Peptidases
Georgia Sotiropoulou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Clinical severity of Alzheimer's disease is associated with PIB uptake in PET
Timo Grimmer et al.
NEUROBIOLOGY OF AGING (2009)
The Precapillary Segment of the Blood-Brain Barrier and Its Relation to Perivascular Drainage in Alzheimer's Disease and Small Vessel Disease
Dietmar R. Thal
THESCIENTIFICWORLDJOURNAL (2009)
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
W. Jagust et al.
NEUROLOGY (2007)
Distribution of 15 human kallikreins in tissues and biological fluids
Julie L. V. Shaw et al.
CLINICAL CHEMISTRY (2007)
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
Katharina Buerger et al.
BRAIN (2006)
Proteinase-activated receptors, targets for kallikrein signaling
Katerina Oikonomopoulou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Substrate specificity of human kallikrein 6 - Salt and glycosaminoglycan activation effects
PF Angelo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins
S Rajapakse et al.
FEBS LETTERS (2005)
Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia
EP Diamandis et al.
CLINICAL BIOCHEMISTRY (2004)
Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies
A Iwata et al.
HUMAN MOLECULAR GENETICS (2003)
Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors
A Magklara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Human kallikrein 8: Immunoassay development and identification in tissue extracts and biological fluids
T Kishi et al.
CLINICAL CHEMISTRY (2003)
Human kallikrein 10 expression in normal tissues by immunohistochemistry
CD Petraki et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2002)
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
DR Thal et al.
NEUROLOGY (2002)
Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients
M Zarghooni et al.
CLINICAL BIOCHEMISTRY (2002)
Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain
K Yasojima et al.
BRAIN RESEARCH (2001)
The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry
CD Petraki et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2001)
Expression of the kallikrein gene family in normal and Alzheimer's disease brain
C Shimizu-Okabe et al.
NEUROREPORT (2001)
Immunohistochemical localization of neprilysin in the human cerebral cortex:: inverse association with vulnerability to amyloid β-protein (Aβ) deposition
H Akiyama et al.
BRAIN RESEARCH (2001)
Human kallikrein 6 as a biomarker of Alzheimer's disease
EP Diamandis et al.
CLINICAL BIOCHEMISTRY (2000)
Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications
EP Diamandis et al.
CLINICAL BIOCHEMISTRY (2000)
Share Paper
